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Abstract 
This report provides TEMAS AG with information regarding the perceptions that 
advanced technology companies and researchers have regarding emerging technologies, with a 
focus on nanotechnology, with regard to risk management. The problem comes from the lack of 
involvement from insurance companies in adequately covering nanotechnologies and other 
emerging risks. Through interviews with advanced technology companies and nanotechnology 
researchers, we concluded that nanotechnology, like all modern technology, has risks, and these 
technologies cannot improve without assuming a certain amount of risk.  
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Executive Summary 
 
Nanotechnologies are a relatively new innovation that have immense potential for 
improving people’s lives. Although they have great potential, there are obstacles to the 
advancement of these technologies, such as the funding of nanotechnology use in everyday 
applications. Nanotechnologies come with many risks and benefits that must be assessed by 
advanced technology companies before going into the market. They must make sure their current 
risk management system is sufficient enough for them to determine any need of insurance. 
Therefore, by understanding how advanced technology companies and researchers deal with 
nanotechnology, whether it be handling them, disposing of them or looking into the potential 
risks of them, we were able to understand their outlook and needs to close the gap between 
advanced technology companies and insurance companies.  
 The goal of this project was to provide our sponsor, TEMAS AG, with an analysis of the 
perceived risks that advanced technology companies and researchers have about emerging 
technology, specifically nanotechnology, as well as their perception about the involvement of 
insurance companies. To achieve this goal, we created several measurable objectives. The first 
objective was to identify what the perceived risks and risk mitigation techniques of 
nanotechnology were according to nanotechnology companies and researchers. To accomplish 
this objective, we interviewed advanced technology companies to determine what safety 
measures they take in order to identify product and occupational risks. We also interviewed 
independent researchers and gathered information on the potential risks of nanotechnologies, as 
well as how they use nanotechnologies safely. With this information, we identified specific risks 
for several nanotechnologies that some companies might try to hide, in order to avoid being 
linked to any of these risks. We believed that independent researchers could speak more 
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objectively about risks than for-profit companies that make these technologies. What we got 
from these interviews is that some companies prefer to handle nanotechnology by using a safe by 
design approach while others think is best to take more risks and have more space to let 
innovation move forward. A safe by design approach is when all the potential risks are taken into 
account and safety measures are shaped accordingly. Some believe a safe by design approach 
reduces innovation because of the many limitations when designing a nanotechnology with 
safety as the main concern.  
The next objective was to determine advanced technology companies’ and researchers’ 
perceptions about the role of insurance companies in managing risks of nanotechnologies. In 
order to achieve this objective, we interviewed advanced technology companies and researchers 
to help us understand how they think insurance should be structured for products that use 
nanotechnology, as well as for the workers who handle nanotechnology. The opinions of the 
companies varied; while some believed insurance companies should learn more about the 
products themselves, others believed that insurance is not as important as an effective risk 
management system. These opinions were split between small and medium sized businesses, 
who rely on insurance to support potential claims, versus large companies, who may have less 
concerns about the financial risks associated with a lawsuit. 
Lastly, we determined the future balance between risks and benefits of nanotechnologies. 
To accomplish this objective, we investigated the literature regarding carbon nanotubes, silica 
nanoparticles, and silver nanoparticles and compared those with interviews we conducted. We 
used this comparison to understand where the field is going and areas insurance companies can 
help companies which are dealing with nanotechnologies. With this comparison, we found a lot 
of discrepancies in the ideas of our interviewees and those portrayed in the literature. For our 
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comparison of silica nanoparticles, we found that while the literature shows the huge danger for 
dealing with nanotechnology, tunneling companies in Switzerland are still operating at three 
times the exposure of silica as that in the rest of europe and is showing no signs of changing. 
When we looked into silver nanoparticles, we found an overwhelming lack of interest and worry 
regarding the environmental implications the literature has shown significant risks of increased 
silver nanoparticle concentration specifically in algae and fish lowering their photosynthetic 
yield and cellular metabolic rate respectively. Lastly, we looked into the comparison between 
carbon nanotubes and found the perceived risks shown in the literature to not be completely 
informed, while we believe this may be due to negative perception, through our interviews we 
found that carbon nanotubes do not have a structure similar to asbestos but a similar aspect ratio. 
With this, in order to replicate the health implications characteristic of asbestosis, one must 
manufacture carbon nanotubes to agglomerate in a similar size and structure while also 
replicating the rigidity. 
In conclusion, with the help of our sponsor, we assessed the information that we received 
from the advanced technology companies and researchers in order to determine how advanced 
technology companies and researchers perceive and handle the risks of nanotechnologies in 
Switzerland. This analysis helped TEMAS AG come closer to understanding how advanced 
technology companies are handling nanotechnologies, as well as the reasons why insurance 
companies have not been as involved in assessing and determining the best approach to 
managing and insuring nanotechnology.   
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1.0 Introduction 
 Applications of advanced technology are becoming more apparent in everyday life.  
With the new risk assessment business model the world is quickly adopting, risk management is 
at the forefront of most companies’ minds and is included in manufacturing standards 
(International Organization for Standardization [ISO], 2018). With the focus on product 
development risks, insurance companies must look into the risks associated with a company and 
determine if their current risk management system is sufficient for them to insure confidently. 
Nanotechnologies are great examples of advanced technologies that have emerging risks and 
benefits. Development of products using this technology, that is extremely small, can have an 
enormous impact on product development in the areas in which they are used. According to 
Carney, Chen, & Murray (2008), nanotechnology refers to the branch of technology that studies 
the application of materials, particles, and devices that measure anywhere between one to one 
hundred nanometers (10-9) in size. There are producers who will manufacture the 
nanotechnologies and companies that use the nanotechnologies for commercial purposes. What 
is important is that the companies that intend to use the nanotechnologies must know and assess 
all the potential risks and benefits before safely using the technology on a commercial scale.  
 In spite of the benefits that are coming out of nanotechnology advances, one problem 
remains clear, which is insuring them. Insuring a new technology can be difficult, but when it 
comes to nanotechnology, it is especially hard. According to Carolyn Aldred (2004), with what 
little is known regarding the safety and proposed risk of nanotechnologies, insurance companies 
feel they do not have enough information in order to take steps towards insuring them. Quoting 
the International Organization for Standardization’s introduction on health and safety practices in 
occupational settings, “The field of nanotechnologies is advancing rapidly and is expected to 
2 
 
impact virtually every facet of global industry and society” (International Organization for 
Standardization [ISO], 2018, pg. vi ). With this increase in nanotechnology applications it is 
important that in order to take steps in the right direction, insurance companies must be able to 
get information on nanotechnologies and their risks, so that their employees will be able to make 
decisions about whether to insure these new technologies.  
 Understanding the risks of products that use nanotechnology is important in ensuring 
public safety. Studies have found that 29% of citizens in Europe believe nanotechnology would 
improve their way of life, but over 65% did not understand the topic (Siegrist, 2007). This shows 
that there is a lack of knowledge and understanding of the risks and benefits associated with 
nanotechnology (Waldron, Spencer, & Batt, 2006). Some studies have also found that citizens in 
Switzerland do not really have a positive nor negative view of nanotechnologies, implying they 
have a more pragmatic approach towards nanotechnology (Burri, 2007). Although this lack of 
knowledge is a problem, Switzerland is approaching this situation by creating citizen panels to 
involve the public in conversations about nanotechnology (Burri & Bellucci, 2008). 
Even though Swiss citizens do not have a positive or negative opinion about 
nanotechnology, they are insisting on better communication regarding research activities that 
could help drive development of safe products and devices. Insurance companies in Switzerland 
have the same perceptions as other Swiss citizens; they do not have enough information to 
determine if the benefits outweigh the risks in order to decide if they should insure any given 
nanotechnology (Michelson & Rejeski, 2006). TEMAS AG is a small consulting company 
located in Zürich that focuses mainly on determining the risks and benefits of nanotechnologies. 
They are interested in closing the information and education gap between insurance companies 
and nanotechnology companies. 
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The goal of this project was to determine the perceived risks that advanced technology 
companies and researchers have about emerging technology, specifically nanotechnology. In 
order to achieve this goal, our objectives included identifying what the perceived risks and risk 
mitigation techniques of nanotechnology are according to nanotechnology companies and 
researchers of nanotechnology, determining advanced technology companies’ and researchers’ 
perceptions about the role of insurance companies in managing risks of nanotechnologies, and 
determining the future balance between risks and benefits of nanotechnologies. To conduct this 
research, we used interviews with employees at advanced technology companies and researchers. 
This research provided our sponsor, TEMAS AG, a way to move ahead with helping to support 
Switzerland’s developing nanotechnology industry.   
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2.0 Background 
Insurance companies require more information on nanotechnologies in order to insure 
their use in many different products. They must be informed about the applications of 
nanotechnologies as well as the associated benefits and risks of these nanotechnologies. How 
best to inform insurance companies as well as the general public about such complex subjects 
isn’t a simple task.  
In this chapter we will define what nanotechnologies are and discuss what research on 
nanotechnology applications is ongoing, what nanotechnologies are already in use, and what the 
risks, benefits, and general perceptions of these technologies are. The safety and effectiveness of 
these nanotechnologies is important information for insurance companies as well as the public. 
We will also review what insurance companies are currently doing about nanotechnologies, what 
their perceptions of nanotechnologies are, what government regulations have been set in place 
for nanotechnologies, and how to approach educating highly trained adults about topics such as 
nanotechnologies. 
2.1 What is Nanotechnology? 
 Despite its name, the field of nanotechnology is an extremely large and diverse field. 
According to Carney, Chen, & Murray, (2008), nanotechnology includes any material, particle, 
or device that measures anywhere between one nanometer to a hundred nanometers, which is 
equivalent to a billionth of a meter to a hundred billionth of a meter. The simplest definition of 
nanotechnology is “technology on the nanoscale” (Nasrollahzadeh, Sajadi, Sajjadi, & Issaabadi, 
2019).  Although this is a very simple definition, it is too broad of a definition. A more 
descriptive definition of nanotechnology is “atomically precise technology.”  
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Although nanotechnology is a type of technology that was just recently created by 
researchers, it is found in nature and includes the major macromolecules such as proteins, 
carbohydrates, DNA, etc. (Nasrollahzadeh et al., 2019). These macromolecules make up the 
cellular structures and are the ingredients for life. Just by looking at what these macromolecules 
are able to do, we can only imagine the extent to which nanotechnology can be used. The 
scientific field of nanotechnology is relatively new, but the magnitude of this field is increasing 
rapidly. The following sections will focus on the applications of nanotechnologies as well as the 
risks and benefits associated with them.  
2.1.1 Applications of Nanotechnology 
 Since the field of nanotechnology is so diverse, there are many useful applications. As 
with any group of technologies, these applications can benefit people’s everyday lives without 
them knowing at all. According to Hawk’s Perch Technical Writing (2019), a few of the areas in 
which nanotechnology is used include, but are not limited to: medicine, electronics, 
manufacturing, and food.  
 The medical field benefits greatly from the applications of nanotechnology. Just in the 
last two decades there have been many nanoparticle-based therapeutic agents that have been 
developed for the treatment of cancer, infections, allergies, and many more (Zhang et al., 2008). 
These technologies allow for a more effective means of drug distribution throughout the body, 
extension of the product life cycle, and ultimately a reduction in health-care costs. One example 
of an extensively researched nanoparticle drug delivery platform is the polymer-drug conjugate. 
This nanoparticle can overcome the undesirable adverse effects of previous drug delivery 
platforms. One of the effects includes the short circulation half-life, which results in frequent 
administrations. According to Wharrad (2015), the circulation half-life of a drug is the duration 
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in which the drug is active. The use of nanotechnology as a drug carrier is extremely useful as it 
can reduce cost and improve the effects of the drug. 
 The electronics field is constantly developing to meet the needs of consumers. Faster, 
cheaper, and smaller electronics are necessary for the evolution of electronics. Researchers have 
been looking for a substitute for silicon-based electronics due to not being able to make them any 
smaller without suffering consequences (Rutherglen, Jain, & Burke, 2009). Through 
nanotechnology research, carbon nanotubes may be one of the candidates that could replace 
silicon-based electronics. These carbon nanotubes will allow for more ideal microelectronic 
components that would eventually create faster and cheaper electronics.  
 In the manufacturing field, researchers are able to create these nanotechnologies with 
different techniques (Mamalis, 2007). Ultra-precision machining refers to the creation of 
dimensional tolerances on the order of 10 nanometers. The CNC ultra-precision machine system 
is capable of three-dimensional control of the position of the tool used for creating such 
nanomaterials. The combination of this machine and processes such as scanning tunneling 
microscopy or the atomic force microscopy allow for ultra-precision machining.  
The food industry also benefits from nanotechnology. According to Hawk’s Perch 
Technical Writing (2019), clay nanocomposites are currently being used as a barrier to gasses 
such as carbon dioxide or oxygen in lightweight bottles, cartons, and packaging films. This 
barrier protects the contents of the container. There are storage bins that are being produced with 
silver nanoparticles embedded within them. These nanoparticles are able to kill bacteria from any 
material that was previously inside of the bins.  
According to the research conducted by Singh, Shukla, Kumar, Wahla, & Bajpai (2017), “The 
nanostructured food ingredients are being developed with the claims that they offer improved 
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taste, texture, and consistency” (p. 2). Not only can nanotechnologies improve the safety and 
shelf-life of food, but they are able to directly affect the attributes of the food that we consume.  
2.1.2 Risks of Nanotechnology 
 Like with many new technologies the risks associated with nanotechnologies are due to 
how little we know about them and how rapidly the field is expanding. Carbon nanotubes, a very 
popular result of nanotechnology, are “100 times stronger than steel and a sixth of the weight, 
and they exhibit high conductivity and unique electronic properties” according to Carolyn Aldred 
(2004, para. 9). Although this is clearly a benefit, in Aldred’s report, Marcel Buerge, head of risk 
engineering for Zurich, Switzerland-based Swiss Reinsurance Company stated, “they have a size 
and shape that is very reminiscent of asbestos, and the comparison is too close to stand aside and 
wait” (para. 10). Obviously, like asbestos and the original inadequate information regarding its 
health risks, several years from now we could have an epidemic due to dangers posed by 
nanotechnologies. The real risk of a nanotechnology comes from its size. Although this is the 
trademark of nanotechnology and is the whole reason useful developments are being made with 
usually not very useful materials, when something is that small, there is no way to know every 
effect it will have on the human body. Many people are concerned about this idea, and in 
Aldred’s report Charlie Kingdollar, Vice President of Stamford, Connecticut-based General Re 
Corporation and author of a Gen Re report on nanotechnology, stated, “concern is building that 
harmful nanomaterials may pass through cellular walls and through the blood-brain barrier” 
(para. 15). If this were to be true, there would be apt reason to fear nanotechnology and be 
worried about what health risks this new technology could pose. Kingdollar went on to say that 
through his research he concluded nanoparticles could cause a multitude of problems including, 
“lung, brain and liver damage in animals” (para. 15). Any time something can pass directly into 
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the system of an organism, the next question is what harm would it cause if it did. Although a 
large concern, the risks nanotechnology poses to health are not the only ones being worried 
about.  
Another fear is what the risks would be in general due to the actual technology. 
According to Muhammed Taher Abuelma’atti (2009), “Simply extending today's weapon 
capabilities by miniaturizing guns, explosives, and electronic components of missiles would be 
deadly enough” (section 5, para. 2) and would obviously be a huge risk we would have to be 
willing to take if we are to research and continue to make innovations using nanotechnology. 
With any new technology, the fear of advanced weapons is always a concern, and it is usually up 
to the benefits to see if the technology is truly worth being researched. A very real and publicized 
fear is that of the “grey goo” or, in other words, a huge mass of replicating nanotechnology due 
to a malfunction or lack of a limiting mechanism. (section 5, para. 2). Though it sounds far- 
fetched and almost out of a sci-fi movie, this concern is very real. Just as factory production has 
turned to robotics over the past few years, nanotechnology may be developed to be self- 
replicating. Going back to the idea of nanoparticles passing through and getting into our bodies, 
Abuelma’aati includes more information regarding carbon nanotubes and their penetrating 
capabilities, “carbon nanotubes… can easily penetrate living cells and even make their way into 
the nucleus, the inner sanctum where DNA resides. In many instances, for reasons that remain 
unclear, the nanotubes themselves killed the cells” (section 5, para 2). If a carbon nanotube is 
able to kill a cell by breaching its nucleus, our next question should be how many would be 
necessary to create an injury or even kill an individual. With the ambiguity regarding 
nanotechnology and its effects on organisms and the planet, many risks are proposed and being 
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researched, but is this balanced at all with the technological advances as a result of these 
technologies? 
2.1.3 Benefits of Nanotechnology 
 Due to nanotechnology, smaller devices are no longer an idea of the past, and as 
mentioned above, exploring materials at the microscopic level, like with carbon nanotubes, can 
create new and stronger materials with unique properties for use in our ever-expanding world of 
technology. Though strong, carbon nanotubes also exhibit electromagnetic properties and 
because of this Abuelma’atti (2009) says, “CNTs will be needed once the classical CMOS 
transistors can be made no smaller – an event now on engineers' radar screens” (section 4, para. 
3). The huge benefit of nanotechnology, as can be inferred, is its size. Due to working on such a 
small scale larger devices are made smaller, and already discovered materials can become more 
useful when explored on the nanoscale. Although not possible yet, Abuelma’atti makes the point 
that once it is figured out, machines could be invented to manipulate matter on the atomic scale, 
leading to some very useful devices that could create new technology atom by atom or even 
recycle old garbage by taking it apart on the atomic level. (section 4, para. 1).  
The medical applications of nanotechnology are where the benefits truly make their 
mark. Dr. Nancy A. Burnham (personal communication, 4/10/2019), a professor at WPI whose 
research area is nanomaterials stated, “Nanomedicine is tremendously exciting” and goes on to 
compare it to chemotherapy, where mostly anything is better than the current treatment available. 
With the current advancement in microelectromechanical systems (MEMS), scientists are 
extremely close to the envisioned microscopic robots of science fiction. With these Abuelma’atti 
(2009) believes we could have “...better design and synthesis of pharmaceuticals; we could 
directly treat diseased cells like cancer; we could better monitor the life signs of a patient; or we 
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could use nanomachines to make microscopic repairs in hard-to-operate-on areas of the body” 
(section 4, para. 2). 
2.2 Nanotechnology Usage 
As with any new technology, there will be regulations set in place to make sure that any 
new innovation is safe. The U.S. Food and Drug Administration (FDA) (2019) has its own 
approach for the regulation of nanotechnology. Any new product must be safe to humans, to the 
environment, to animals, and whatever else it may apply to.  The FDA will maintain a product-
focused and science-based regulatory policy. Each product that includes the use of 
nanotechnology will be evaluated individually. Effectiveness of a technology is very important 
as well. The whole point of creating new technology is to make life easier and more effective. If 
a new product isn’t effective, then there would be no point in investing time or money into the 
product. The companies that create these nanotechnologies must keep these country-specific 
regulations in mind. The following sections will discuss some of the companies that create 
nanotechnologies as well as the safety and effectiveness of nanotechnologies that are being 
developed as well as nanotechnologies that are currently in use. 
2.2.1 Companies Creating Nanotechnology 
 The nanotechnologies being used around the world must be created by someone. There 
are many different companies that are researching and creating these nanotechnologies. One of 
these companies is 4Wave (2019), which provides plasma processing equipment, thin film 
coatings, milling equipment and services to meet challenging vacuum equipment. Another 
similar company is Nanoscan AG (2019), which is based in Dübendorf, Switzerland. This 
company commercializes nanotechnology by developing new products, solutions, and 
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application segments as well as optimizing current methods. They provide a high-resolution 
scanning probe microscope. 
2.2.2 Safety and Effectiveness 
 There must be regulations set in place to monitor and evaluate products for safety and 
effectiveness, and nanotechnology is no exception. Researchers must identify the effectiveness 
of this technology in its applications so that they can continue to improve and understand what 
nanotechnologies are capable of. The Centers for Disease Control and Prevention (CDC) and the 
National Institute for Occupational Safety and Health (NIOSH) have published a pamphlet for 
instruction on safe nanotechnology use in the workplace (University of North Carolina at Chapel 
Hill [UNC] 2019). This pamphlet summarizes different types of nanomaterial hazards and their 
risk levels. The first risk level is a polymer matrix, the second risk level is liquid dispersion, the 
third risk level is dry powders or aerosols, and the final level is dry powders or aerosols with 
known toxicity. All of these risks call for Personal Protective Equipment (PPE) and Engineering 
Controls. The effectiveness of nanotechnology depends on the field in which it is used. For 
example, there has been research conducted by the department of civil and environmental 
engineering at Hanyang University in Seoul, Republic of Korea (Jo, Chakraborty, Kim, & Lee, 
2014). This research on nanotechnology has the aim of developing high performance, smart, and 
sustainable construction material. They researched the effectiveness of top-down nanotechnology 
in the production of ultrafine cement. Their conclusion was that the process that they used was 
able to produce the ultrafine cement of particle size between two hundred to three hundred 
nanometers in size. They expect this cement to influence the properties of the final product. 
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2.3 Perception of Nanotechnology 
The general public is not sure what nanotechnology really means or what it is used for 
(Gaskell, Eyck, Jackson, & Veltri, 2005). Even though there is a lack of knowledge regarding the 
topic, people may have their own perceptions, which could be positive, negative or neutral. In 
the US, citizens are more inclined to have a positive view of nanotechnology, while in Europe 
there is a neutral view when it comes to the benefits and risks of nanotechnology. Insurance 
companies are also involved in this, since they have to be aware of these benefits and risks in 
order to make good judgments when it comes to insurance decision making. They have to be 
well informed in each area nanotechnology can be applied to and how it can be a risk. In the 
following sections the perception of the general public in US and Europe will be discussed as 
well as insurance companies. 
2.3.1 World Perception on Nanotechnology 
Understanding the benefits, risks, regulations, and public perceptions is equivalent to 
successfully assessing the current state of nanotechnology in Switzerland. In recent years, 
various studies have been done with the goal of determining public perception of 
nanotechnology (Cobb & Macoubrie, 2004). Numerous studies compare the American public 
with the European public and explain their similarities and differences. Gaskell, Eyck, Jackson, 
& Veltri (2005) found in their results from one study that around 50% of the respondents in the 
US were optimistic about the usage of nanotechnology, answering the question that it will 
improve their way of life, and 35% said they didn’t know. By comparison, in Europe only 29% 
were optimistic, and 53% said “don’t know” (p. 83-84). It is clear that the American public 
accepts nanotechnology more than Europeans, meaning they have better hopes in the benefits 
nanotechnologies may bring. Americans seem to see nanotechnology as a means of progress, but 
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those who are skeptical are concerned of “losing personal privacy to tiny new surveillance 
devices” (Cobb & Macoubrie, 2004, p. 395), whereas Europeans have taken a “wait and see” 
approach to nanotechnology in general. These differences are present due to the fact that 
people’s acceptance level correlated to how directly they are affected by the applications of the 
nanotechnology. 
Most studies searching for the public’s perception of nanotechnology have only dealt 
with the general meaning instead of going by the application and how it affects people directly. 
Fortunately, Siegrist (2007) found that the way nanotechnology is being used in different kinds 
of fields definitely affects public perception. One main usage that worries people the most is 
using nanotechnology in foods, medicines or any item that is ingestible. 
On the other hand, the media can also play a large role in shaping people’s perceptions. 
Not much information is provided to people concerning nanotechnology, its applications, risks, 
and benefits. If it were to be done, it would likely help experts, people, insurers, etc., when it 
comes to future decision making (Glady, Edward, Garcias & Moses, 2012). Cobb and Macoubrie 
(2004) found that people tend to follow what they hear about technology instead of what they 
actually know about it to make decisions.  
2.3.2 Insurance Companies Perception on Nanotechnology 
As the number of products that use nanotechnology increases, more concerns are rising. 
One of the greatest risks is that nanotechnology will directly impact human health through direct 
contact, but there are also concerns that nanotechnology will have an indirect impact on human 
health through environmental exposure, such as the food chain (Glady, Garcia, & Moses, 2012). 
When it comes to insurers, all they really want is to be confident “that any liability imposed is 
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both reasonable and scientifically supported” (p. 314).  Unfortunately, there currently is not 
enough information, and the following examples illustrate some of these concerns. 
 
A. Health Concerns 
Each nanomaterial contains a different chemical, electrical, and magnetic property, 
which, unlike other elements already found on earth, are unknown, and this raises concerns in 
most industries, since they do not know how each one behaves (Glady, Garcia, & Moses, 2012). 
“Some nanomaterials are not readily found in nature. Therefore, society has a difficult time 
comparing nanomaterials to other similar materials” (p. 321). 
Humans can come directly in contact with nanotechnology due to processes requiring 
nanomaterials to be present in the manufacturing process. An example could be sunscreen that 
contains nanotitanium dioxide, which may cause pulmonary reactions, including inflammation, 
pulmonary damage, and fibrosis (Glady, Garcias, & Moses, 2012). The Centers for Disease 
Control created a guidance document so people can be aware of how to handle the nanomaterial 
and warned that exposure to this type of nanomaterial and inhaling it may result in serious health 
effects. Clearly more investigations on how each nanomaterial behaves have to be completed, 
since there is no conclusive data stating the health and safety risks, and this brings doubts to 
many people. If insurers or the general public would have this type of information available to 
them, when it comes to decision making, they could do so more confidently, but for now no one 
knows the true health effects of these nanotechnologies. 
  
B. Environmental Concerns 
Human health can be affected through the introduction of nanomaterials into the 
environment. This has given rise to concerns for human health as Glady, Garcias and Moses 
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(2012) said, “These concerns are supported by research that indicates biological impacts of 
nanotechnology upon animals and plants in the food chain” (p. 323). There really has not been 
much research on plants, but it surely is raising concerns. Some studies have shown 
nanomaterials impacting germination, the uptake of gold nanoparticles from waste sludge into 
plants, as well as hatching delays and deformities in animals. 
These studies may show the negative impact of nanomaterials for plant and animal life, 
but not all are the same. As an example, iron nanoparticles are used to contain polluted 
groundwater and are anticipated to have a positive impact, even though not much is known as to 
whether it will lead to health issues (Glady, Garcias, & Moses, 2012).  
 
2.4 What Are Insurance Companies Doing About Nanotechnology? 
 Insurance protects individuals and companies from possible risks. Insurance companies 
take into consideration the risks to individuals for a price and supply them with a service that 
could protect them if something happens, for example a car accident or a sickness (Blaunstein & 
Linkov, 2010). Basically, when a company or individual does not want the risks to occur, they 
buy insurance to transfer the risk to the insurance companies. For businesses, the safety net of 
insurance is extremely important when trying to attract investors. Without insurance, something 
could go wrong, and the company could be out of a lot of money or even go out of business. 
However, with insurance, if something were to go wrong, the insurance company would cover 
the expenses from this problem. The risk of something going wrong is then transferred to the 
insurance company instead of the business. However, in the case of nanotechnologies, insurance 
companies are unsure about how to insure them. 
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2.4.1 Insurance Policies Dealing with Nanotechnology 
 Not only is insurance good for innovation, but innovation is good for insurance 
(Blaunstein & Linkov, 2010). From the insurance perspective, innovations, such as with 
nanotechnology, could reduce some risks. These new technologies could create stronger 
buildings, improve medical procedures, and replace hazardous materials, decreasing the risks in 
multiple different industries. With such new technology, it can sometimes be difficult for 
insurers to figure out how to insure these products. Along with the fact that nanotechnologies are 
new, they are also growing and improving fast; this makes it hard for underwriters to obtain 
current information about these technologies and appropriately insure them (Schoolman & 
Kingdollar, 2013). In 2013, many insurance companies were pretending that nanotechnologies 
were not a problem yet; they thought of it as something that will come in the future. However, it 
appears they are too late already. Underwriters typically analyze the past and rely on past events 
to determine pricing, so the fact that nanotechnology is so new makes this process difficult 
because there is no history to look back on (Gorski, 2015). Many insurance companies have yet 
to create coverage specifically for nanotechnology and have yet to create an exclusion for 
nanotechnologies, which causes businesses to assume they are covered for nanoproducts they 
use. 
2.4.2 Traditional Risk Management Strategies 
 Acceptable risk is one of the most common risk management models used for hazardous 
agents (Marchant, Sylvester, & Abbott, 2008). This models requires “risk assessment to describe 
the risks of an agent, and then see to reduce risk to levels that are socially acceptable” (p. 44). 
Due to the fact that nanotechnology and its risks and benefits are not very well known, this 
model is very difficult to use. Because nanotechnology is a newer field, there is very little to no 
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data regarding their risks so it becomes more difficult to estimate possible risks. Additionally, 
nanotechnology is actively growing and evolving, so risks that could be true now, could be 
completely different a year from now. This makes it more difficult to assess risk because, other 
than the lack of historical data, the historical data that is available could no longer be accurate.  
2.4.3 When Do the Benefits Outweigh the Risks for Nanotechnologies? 
 According to Blaunstein and Linkov (2010), if nanotechnologies are able to help reduce 
the risks in a variety of industries, such as creating stronger materials or reducing damage from 
natural disasters, this could be beneficial for the insurance companies. If this technology could 
reduce these risks, this would be less money being paid out from the insurance companies to 
cover the costs of these disasters.  
2.4.4 Risk Assessment Regarding Nanotechnology 
 At the moment insurers are very skeptical about dealing with nanotechnology (Aldred, 
2004). With parallels already made to asbestos, insurance companies most likely are very fearful 
that insuring a new technology in which little is known about would backfire. As introduced in 
section 2.1.3, Buerge believes, “The reason why we have a question mark over nanotechnology 
is that not enough is known about nanoparticles' behavior when they come in contact with living 
organisms” (para. 4). Though most risks are not assessed completely, when looking at a new 
technology, it is better to approach it as having a negative impact rather than disregarding any 
risk and dealing with the consequences later. 
2.4.5 Current Protocol in Place to Deal with Nanotechnology 
 There is not much in the way of protocol regarding insuring nanotechnologies at the 
moment, but insurance companies and nanotechnology companies are taking steps in the right 
direction. For example, one insurance company, Zurich, “has developed a web-based software 
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product which looks at nanoparticle characteristics to assist nanotechnology users determine 
potential hazard levels” (Wright, 2010, para. 1). This is a huge step when it comes to insuring 
nanotechnology in which the biggest problem is the inadequate information that is relayed and 
the insufficient knowledge needed to calculate risk of a certain nanotechnology. With software 
such as that proposed above, even without a great understanding of nanotechnology insurance 
companies would at least know how hazardous the technology is. Porter Wright also wrote about 
another company “Lexington Insurance, who has created an integrated coverage insurance policy 
specifically for nano clients, especially those who may need special assistance in gauging the 
level of risk management in the field” (para. 1). This is another big step to improved relations 
between the two types of companies and would help the nanotechnology field to continue to 
expand. 
2.4.6 Government Regulations  
As with many new technologies regulation is often a difficult task, and, as discussed 
earlier and mentioned in the statement regarding the FDA’s approach toward nanotechnology 
regulation, “The very changes in biological, chemical and other properties that can make 
nanotechnology applications so exciting, however, also may merit examination to determine any 
effects on product safety, effectiveness, or other attributes” (FDA, 2018, para. 1). The FDA’s 
goal in this regard is to ensure a safe and responsible development process for nanotechnology. 
To that end they outlined the regulatory approach they will be taking including the following 
attributes,  
● FDA is maintaining its product-focused, science-based regulatory policy;  
● FDA’s approach respects variations in legal standards for different product-classes; 
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● Where premarket review authority exists, attention to nanomaterials is being incorporated 
into standing procedures; 
● Where statutory authority does not provide for premarket review, consultation is 
encouraged to reduce the risk of unintended harm to human or animal health; 
● FDA will continue post-market monitoring; 
● Industry remains responsible for ensuring that its products meet all applicable legal 
requirements, including safety standards; 
● FDA will collaborate, as appropriate, with domestic and international counterparts on 
regulatory policy issues; 
● Both for products that are not subject to premarket review and those that are, FDA will 
offer technical advice and guidance, as needed, to help industry meet its regulatory and 
statutory obligations (para. 3). 
(See Appendix C for more information regarding the FDA’s approach towards regulating 
nanotechnology.) With nanotechnologies being such new technologies that are very early in 
development, there are not many regulations as of yet. When more is known about the benefits 
and risks regarding these new advancements, new regulations will most likely need to be put into 
effect. 
2.6 Nanotechnology in Switzerland 
Switzerland is one of the countries with the largest investments in nanoscale research 
worldwide (Burri, 2007). Although, in contrast to that, there is a lack of public knowledge 
regarding nanotechnology because there is not sufficient information for citizens to make 
decisions. To tackle this problem, Switzerland has created citizen panels to include people in 
discussions about nanotechnology. Studies have found that citizens in Switzerland do not really 
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have a positive nor negative view about nanotechnologies and have a more pragmatic approach 
to them. Citizens do not fear the risks, nor are they enthusiastic about the benefits. Instead, they 
want research to continue to gather more information so people can be better informed. 
2.6.1 Swiss Perception of Nanotechnology 
In an article about Switzerland and nanotechnology, Burri (2007) mentioned, “In a survey 
of the European Commission, Switzerland is listed 17th for the largest public expenditures in 
nanotechnology worldwide. Taking the funding of the private industry into account as well, 
Switzerland’s investment in nanoscale research is very large” (p. 143). 
 Switzerland’s scientific knowledge really does not have a firm ground in the current, 
early phase of research and development of nanotechnologies, which has created a challenge for 
citizens to be involved in discussions and making decisions on what nanotechnology truly means 
(Burri, 2007). Switzerland has created many forums for public debate, and citizen juries have 
been organized to understand the public's perceptions about nanotechnologies in numerous 
countries. 
The Centre for Technology Assessment (TA-Swiss) organized a citizen panel called the 
publifocus in the fall of 2006 to increase public engagement in these types of topics (Burri, 
2007). The focus group in the nanotechnology panel, which involved representatives from 
stakeholder groups, showed that the participants didn’t really have a positive or negative view, 
meaning they have a more pragmatic approach towards nanotechnology. Participants in these 
studies neither feared risks nor showed enthusiasm about its benefits, but overall ranked benefits 
higher than risks. Another thing the panel and citizens thought was that there needs to be better 
clarifications and better communication on research activities, which would help the public 
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inform themselves on future developments, applications of nanotechnologies and the potential 
risks they can bring in any areas (Burri & Bellucci, 2008). 
 In the following chapter, the methods we used to collect data on the perceived risks that 
advanced technology companies, researchers and insurance companies have about emerging 
technology, specifically nanotechnology, will be described in full detail.  
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3.0 Methodology 
The goal of this project was to provide TEMAS AG with information about the perceived 
risks and benefits that advanced technology companies and researchers have about emerging 
technology, specifically nanotechnology, as well as their perception about the involvement of 
insurance companies. 
Our measurable objectives were: 
1. Identify what the perceived risks and risk mitigation techniques of nanotechnology are 
according to nanotechnology companies and researchers of nanotechnology; 
2. Determine advanced technology companies’ and researchers’ perceptions about the role 
of insurance companies in managing risks of nanotechnologies.  
3. Determine the future balance between risks and benefits of nanotechnologies. 
 In the following sections, we will describe in detail the methods we used to achieve each 
objective and why we have selected these methods. 
3.1 Identify The Perceived Risks of Nanotechnology According to Companies and 
Researchers 
 In order for us to identify the needs of advanced technology companies, we interviewed 
one employee from six different advanced technology companies to determine the perceived 
risks they have with their nanotechnology products, as well as if they believe there should be 
better plans in place to provide coverage for advanced technology applications. This information 
helped us determine what their needs were and gave us examples of some emerging risks 
insurance companies should be taking into account.  
In addition to speaking with advanced technology companies, we carried out interviews 
with two independent researchers who develop or work with nanotechnology. We did this 
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because researchers could speak more objectively about the perceived risks of nanotechnology 
than the advanced technology companies. The information gathered from the researchers also 
gave us a better understanding of insurance and risk management involvement. 
3.1.1 Interviews with Advanced Technology Company Employees 
 To understand what advanced technology companies perceive as risks for 
nanotechnology, we conducted interviews with one employee from six different advanced 
technology companies. These companies dealt with carbon nanotubes, carbon black, graphene, 
silica nanoparticles, and silver nanoparticles. Most of the employee’s positions were in research 
and development and one of the interviewees was Chief Executive Officer (CEO) of the 
company. Out of the total of six interviews with advanced technology companies we had, four 
companies were considered small and medium sized companies, defined as less than 250 
employees, and two were considered large companies. These interviews lasted about 20-30 
minutes and discussed the companies’ perceptions about risks for their nanotechnology products.  
The interview included questions about what products they had and if they were thinking 
about the potential risks that their products could pose in both the short term and long term. The 
information received from these interviews helped us understand what advanced technology 
companies have for nanotechnology products as well as the potential associated risks for these 
products. These companies were selected with the help of our sponsor’s and WPI alumna’s 
connections. Additionally, these companies all produce or use emerging technologies. See 
Appendix B for the protocol for these interviews.  
3.1.2 Interview with Researchers of Nanotechnology 
 We reached out to two researchers of nanotechnology within Switzerland and conducted 
interviews with each of them. These interviews included questions regarding the risks that their 
24 
 
research projects have and lasted 40-50 minutes. These researchers were also selected with the 
help of our sponsor’s and WPI alumna’s connections. Although the interviews with researchers 
could be a little more specific in terms of risks of nanotechnology, the same general interview 
questions were used for companies and researchers. During the interviews, there were additional 
questions added to make the interviews more conversational. With the researchers, these 
additional questions often went more in depth on the specific nanotechnology and research 
projects. See Appendix B for the general interview protocol. 
3.2 Determine the Perception About the Role of Insurance Companies According to 
Companies and Researchers  
 In order to determine the perception of advanced technology companies and researchers 
about insurance companies’ role with nanotechnology, additional questions were asked in the 
interviews mentioned in the previous sections (3.1.1 and 3.1.2). These questions were related to 
the companies’ and researchers’ products and general liability insurance. This information 
helped us identify what these companies and researchers believe insurance companies should be 
doing to deal with these emerging technologies. 
3.2.1 Interviews with Advanced Technology Company Employees and Researchers 
The interviews detailed in section 3.1.1 also included questions regarding if they had 
insurance, if they received what was expected from their insurance company, and what the 
companies’ and researchers’ risk management systems are. The information received from these 
interviews helped us understand what advanced technology companies have for insurance and 
whether they are protected by their insurance plan. 
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3.3 Determine the Future Balance Between Risks and Benefits of Nanotechnologies 
 In order to find where the balance lies between the risks and benefits of nanotechnology, 
we looked into the literature regarding the three more well researched fields of nanotechnology: 
carbon nanotubes, silica nanoparticles and silver nanoparticles. We then compared those with the 
responses from the interviews we conducted. This in turn helped us understand where the field is 
going as a whole, and in what areas insurance companies could look into within the three 
nanotechnologies we focused on. 
3.3.1 Literature Regarding Nanotechnology 
 
 To compare the views between our interviewees and researchers, we decided to look into 
the literature of three different nanotechnology applications. The three fields we looked into were 
carbon nanotubes, silica nanoparticles, and silver nanoparticles. To make this comparison, we 
looked at the risks and benefits of these specific technologies in order to find the balance 
between the perception found in the literature and that discussed in our interviews. These three 
fields have a lot of research done on them and provided us with a lot of information to analyze 
regarding the risks and benefits of these technologies. 
3.3.2 Interviews with Advanced Technology Company Employees and Researchers 
 In the same interviews mentioned in the previous sections (3.1.1, 3.1.2, and 3.2.1), we 
asked advanced technology company employees and researchers to speak objectively about the 
risks and benefits of nanotechnology. We then took this information, as well as that gathered 
from the literature, and compared the two in order to understand where the field should go as a 
whole and where insurance companies can help those dealing with and exposed to 
nanotechnology. 
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3.4 Summary 
 The methods described above were used to complete the group’s goal: to provide 
TEMAS AG with information about the perceived risks and benefits that advanced technology 
companies and researchers have about emerging technology, specifically nanotechnology, as 
well as their perception about the involvement of insurance companies. In the following chapter 
we present and analyze the results that were gathered by the use of our methodologies. By 
analyzing our results, we were able to reach our conclusions. 
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4.0 Results and Analysis 
Our goal of this project was to provide TEMAS AG with information about the perceived 
risks and benefits that advanced technology companies and researchers have about emerging 
technology, specifically nanotechnology, as well as their perception about the involvement of 
insurance companies. In this chapter, we will present the results of our research to show how we 
achieved our objectives and ultimately achieved our project goal.  
4.1 Identify The Perceived Risks of Nanotechnology According to Companies and 
Researchers 
Through our interviews with both advanced technology companies and researchers, we 
identified what they thought about the risks posed by nanotechnology, as well as risk mitigation 
techniques for nanotechnology.  
 4.1.1 Determine The Greatest Risks Posed by Nanotechnology 
One researcher that we talked to discussed the greatest risk posed by nanotechnology to 
be the misuse of these nanotechnologies. He believes that the general misuse of novel technology 
is a main risk in the world. There are many technological advances that provide great benefits to 
humanity, however their misuse can lead to harm as well. For example, cars provide humans 
with a great means of transportation and allow for a simple and fast way to get to where you 
need to be. Yet if the vehicle is misused by the driver, people could be severely harmed or killed. 
There lies this risk with many technologies, but the benefits often outweigh the risks in these 
situations, therefore we continue to utilize them.  
The same researcher explained that another high risk with nanotechnologies is free 
particles. During their research, they realized that the lungs are most susceptible to 
nanotechnology damage. If there are free particles in the air, people who work with 
28 
 
nanotechnology that are exposed could easily breathe them in and risk harming their lungs. 
Therefore, they take precautionary measures to either suspend the particles within a substance, 
such as a gel, or just avoid powders at all costs. Another advanced technology company that we 
interviewed approached this issue the same way. They produce electrodes and they suspend 
carbon black nanoparticles within a gel so that the nanoparticles cannot float freely in the air. 
Another way to approach risk mitigation of airborne particles according to the ISO standard 
regarding occupational risks is stated that, “the decision to use respiratory protection should be 
based on professional judgement that takes into account toxicity information, exposure 
measurement data, and the frequency and likelihood of the workers’ exposure” (International 
Organization for Standardization [ISO], 2018 pg. 29). 
Another interviewee discussed that they believe the main risk of nanotechnology has 
nothing to do with the material itself. He believes that the public perception of these advanced 
technologies is the biggest risk because it can completely change the way people look at the 
product. For example, carbon nanotubes were brought to the public by explaining how they are 
similar to asbestos because of their mechanical design, not their chemical design. One 
interviewee explained that although these two materials can have the same aspect ratio, they are 
very different when it comes to size. Since carbon nanotubes are smaller than asbestos crystals, 
they do not have the same risk of puncturing the lungs due to the fact that macrophages within 
the body can dispose of the carbon nanotubes. However, it was brought to the public’s attention 
that they are very similar, so they would be less trustworthy of anything using this material. The 
public’s perception of a material could very easily stop any innovation from occurring using 
these materials. More research can be done with insurance companies to find out if they have 
similar perceptions to the public.  
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4.1.2 Determine How Advanced Technology Companies’ Mitigate Nanotechnology Risks 
 Every company interviewed had a different approach to mitigating the risks of their 
advanced technologies. In most cases, small and medium sized companies had a higher risk 
compared to larger companies because they had employees who physically handled these 
nanotechnologies, while the larger companies were able to use machines and work in a 
completely enclosed area where no personnel could be exposed to any potential hazards. 
As mentioned by one of our interviewees, Rudolf Bieri, some companies are not really 
careful on how they handle these types of materials. He mentioned that big industries, such as the 
battery industry, are not really careful when it comes to handling their products because they are 
unaware of the risks and do not take the necessary precautions. They tend to trust past 
procedures when dealing with nanopowders and similar dangers that their workers often do not 
wear gloves and do not think there is anything wrong, when in reality contact with these 
materials could potentially lead to health problems. To put it in perspective, Rudolf Bieri’s 
company, Stat Peel, takes the necessary precautions to mitigate any possible risk associated with 
nanotechnologies because they know the risks and the potential outcomes by conducting 
research. His company is focused on creating devices that analyze how much a person is exposed 
to certain nanoparticles on a daily basis. The way his employees handle and dispose of the 
nanoparticles is with a flow box; there is no powder handling outside of a biological flow box 
since some nanomaterials can be aerosolized very easily.  
Other researchers and companies that could be considered as small and medium sized 
have taken the same approach when handling and disposing of their nanotechnologies. They 
have treated nanotechnology as a high risk, and if they take all precautionary measures, there 
will most likely be no harm when dealing with nanoparticles. Some researchers also discussed a 
30 
 
safe by design approach. A safe by design approach is when all the potential risks are taken into 
account and safety measures are shaped accordingly. 
Although the safe by design approach is used by multiple companies and researchers due 
to its concern for safety and risk mitigation, others thought it was not the best approach. One 
interviewee mentioned that by using the safe by design approach, innovation is greatly reduced 
because of the many limitations when designing a nanotechnology with safety as the main 
concern. If a company is too focused on avoiding risk by looking for potential risks, they will 
find themselves without much room to investigate and conduct research for innovations. 
 Another approach taken when mitigating occupational risks was by using machines in the 
work space instead of physically handling certain products. One interviewee from a larger non-
nanotechnology company uses this type of method to deal with its risks and ultimately has 
created a zero risk environment. The machines allow for workers to avoid any type of danger 
since the machines are in an enclosed area where no one is really at risk of being exposed. 
 Although we interviewed eight companies and researchers, there were also two 
companies that we contacted that did not want to speak with us. This might have been because 
they did not find the matter to be important, or because they did not believe that they had any 
risks that needed to be addressed. One of the companies said that they have no human contact 
with the nanotechnology that they develop, therefore they are not worried about any risks within 
the facility. We exchanged many emails with the other companies, but once we sent our 
interview questionnaire to them over email, they said that they were not able to answer our 
questions and did not respond anymore.  
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4.2 Determine the Perception About the Role of Insurance Companies According to 
Companies and Researchers  
 Through our interviews with advanced technology companies, we found that small and 
medium sized businesses, defined as less than 250 employees, generally have the same opinions 
about the need for product and general liability insurance, while large companies generally have 
similar opinions; however, these opinions are different from those of small companies. Out of the 
total of eight interviews with advanced technology companies and researchers we had, four 
companies were considered small and medium sized companies, two were considered large 
companies, and two researchers. Small and medium sized companies believe that insurance 
companies should make specific insurance policies for nanotechnology. One company that we 
interviewed thinks insurance companies should learn more about what they are actually covering 
with their policies. If nanotechnologies are included in a policy that covers chemicals, there 
could be unforeseen outcomes that the insurance companies did not foresee coming because they 
were unaware what nanotechnologies really include.  
 One large company that we interviewed explained that they do not think their advanced 
technologies have many risks. They believe that insurance is not the most important thing for 
their products. Instead, they think a proper risk management system would help to mitigate any 
risks. In case a problem was to occur, large companies could afford to have just a good risk 
management system because they have more resources to be able to handle any potential 
lawsuits against them. However, if a small company did not have insurance and something went 
wrong, the whole company could go bankrupt from a lawsuit brought against their product. 
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Figure 4.2.1: Response to an interview question about risk management and insurance. (Sample size 8) 
 According to Figure 4.1.1, the answers to the question are divided evenly among small 
companies, but based on our interviews, there were more large companies that thought a good 
risk management system was better than having insurance. As one of our interviewees said, a 
good risk management system is essential because there comes a time when insurance cannot 
always help. For example, if a person was to inhale a nanoparticle and then years later find out 
they have contracted a disease due to the nanoparticle, insurance may not be able to fully resolve 
the problem. The only way to help in this case would be to have prevented this from happening 
by having a good risk management system. 
A lot of insurance sector individuals we reached out to did not want to let us interview 
them or fill out a survey. Though this meant we did not get direct responses on their views about 
advanced technology, their lack of response is a result in and of itself. Through interviews with 
advanced technology companies, researchers, and the information we received from our sponsor, 
we discovered that it is likely that insurance companies lack interest and education about 
nanotechnologies and the associated risks. One researcher explained that insurance companies 
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see nanotechnology as a high risk, therefore they would charge higher premiums for a risky 
technology. He also explained that Europe is different from the United States in that you are less 
likely to be involved in litigation as a result of a product’s potential harm. Since the companies in 
Europe are not as likely to get sued, they might not worry about safety precautions as much.  
During our interviews with both advanced technology companies and researchers, we 
asked our interviewees about their thoughts on how insurance companies should approach 
emerging technologies. One researcher said that insurance companies should be supportive when 
dealing with emerging technologies. They should carefully take the time to assess both the risks 
and benefits of a particular technology.  
 
Figure 4.2.2:  Percentage of interviewees who think insurance companies should deal with emerging 
risks in selected methods. (Sample size: 8) 
 
 Figure 4.4.1 shows the responses from our interviewees when asked how insurance 
companies should handle emerging risks in today’s world. From among eight interviewees 50% 
of them expressed that insurance companies should educate themselves on nanotechnology and 
34 
 
create more specific policies for this field. One interviewee stated that the insurance companies 
should be aware about what is going on in the industry in order to effectively cover these 
products. The same interviewee also explained that insurance companies should stop using 
backward thinking and start looking forward. With the ever changing field of nanotechnologies 
and other emerging risks, looking at past data will not help with determining how to insure these 
products. About a quarter of the people we interviewed expressed that insurance companies 
should focus on preventing the risk. While this should be covered by a good risk management 
system, with insurance companies helping to mitigate the risks, better procedures may be put into 
place and premiums may be decreased benefiting both sides. By helping advanced technology 
companies mitigate their risks and prevent things from going wrong, there will be less that the 
insurance companies will have to cover in the future. 
4.3 Comparison of Literature and Interviews 
To analyze the perception of risks and benefits in a more concise way, we researched 
three specific types of nanotechnology which contained the most research and compared the 
risks and benefits to those perceived by advanced technology companies and researchers we 
interviewed. The three areas chosen were carbon nanotubes, silica nanoparticles, and silver 
nanoparticles.  
First looking at carbon nanotubes, from the literature we found an overwhelming fear of 
this technology due to its similar structure to asbestos (Aldred, 2004, para. 10). However, with 
further inquiry into the risks of carbon nanotubes with our interviews, we learned from Dr. Peter 
Wick (personal communication, 09/23/19) that, “Carbon nanotubes do not actually have a similar 
structure to asbestos, but a similar aspect ratio meaning they are both needle like in structure, but 
differ in size and chemical composition. When carbon nanotubes agglomerate to structures 
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similar to long and stiff needles, then there are evidences to cause related symptoms like 
asbestos.” With this information, we interpreted this as, while partially correct about the shape of 
carbon nanotubes, some people may be overreacting to the potential danger posed by carbon 
nanotubes as they would need to be manufactured at a similar size and shape. From one of our 
interviews we received a good way to explain this, and that is to think of carbon nanotubes as 
cooked spaghetti while thinking of asbestos as uncooked spaghetti. With asbestos this would be a 
rigid structure, while with carbon nanotubes it would be much more malleable and thus would 
not cause the same health problems as asbestos. The only way that carbon nanotubes will cause 
the same damage is if they were stacked and shaped in a needle like structure. 
Moving on to the risks posed by silica, the literature is pretty clear in what it is trying to 
portray, and that is regarding the injuries that could be caused from silica particle inhalation. A 
member of the Scripps Research Institute, Kenneth Michael Pollard (2016), stated, “the 
pathophysiology of silicosis consists of deposition of silica particles in the alveoli of the lung. 
Ingestion of these particles by macrophages initiates an inflammatory response, which stimulates 
fibroblasts to proliferate and produce collagen. Silica particles are encased by collagen leading to 
fibrosis and the nodular lesions characteristic of the disease” (para. 1). Along a similar vein, we 
found from one of our interviewees, Rudolf Bieri (personal communication, 9/24/19), “that the 
tunneling industry is very involved in airborne silica levels and currently the occupational limit 
for those working in the field is three times that of the rest of the European Union, but with a 
lowering of said limit, more special precautions would need to be taken for tunneling, and thus 
companies involved are trying to push back legislation regarding this limit as much as possible.” 
This shows that while a potential hazard, companies and the people running those companies 
involved in the tunneling industry are not too worried about silica exposure and are willing to 
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take on that risk, instead of changing the way things are done to provide a one hundred percent 
risk free environment. With this we find that while people may be stuck in their ways and thus 
do not want to change, there is a significant risk and measures should be taken to minimize this. 
When looking at the risks involved with silver nanoparticles, we found that in a study 
done by Yang Yue, et al. (2017, p. 5) raised a lot of concern in terms of toxicity for fish from 
silver nanoparticles, while our interviewees did not express as much concern. The literature 
mainly focused on nano silver applications that involve textiles and clothing, emphasizing the 
point that when washed these particles tend to fall off and get into the water stream. The big fear 
of this is that the greater concentration of silver nanoparticles in water sources around the globe 
could have a huge unforeseen environmental impact. 
 
Figure 4.3.1: Contrasting the effects on both algae and fish regarding cellular concentration of AgNP and 
AgNO3. 
 
 As shown in this figure, there is a direct negative correlation between the cell concentration of 
AgNP and both cellular metabolic activity and photosynthetic yield in fish and algae 
respectively. Though this fear was mentioned in multiple interviews, most interviewees claimed 
that there has been no solid proof that silver nanoparticles have any impact whatsoever in the 
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environment. The accumulation of silver nanoparticles in both plants and animals has been 
experimented with and has shown convincing evidence that a surplus of silver nanoparticles in 
our water supply could have a drastic effect. From our interviews, it almost seems that this 
information is not being showcased and thus people in the field may not be as knowledgeable as 
they should be regarding the environmental effects of silver nanoparticles. We assume this may 
be due to the lack of knowledge among our interviewees in the specific field of silver 
nanoparticles, however we are not sure. 
 In general, it seems as if the views of the literature contain views that are different to the 
actual risks regarding nanotechnology posed by those in the field. While the research regarding 
silver nanoparticles argues the opposite very strongly, in both the applications of carbon 
nanotubes and silica nanoparticles, the fear may be uncalled for. This may be due to the public 
perceptions of new technology, however in today's world people are concerned most about the 
risks and unforeseen risks of any new innovation. In the end, nanotechnology is like any other 
emerging technology in the sense that it should be approached with caution, however some risk 
must be assumed in order to further the field. Others may not agree, but at the end of the day we 
realized that the current safe by design approach for dealing with nanotechnology sets up 
roadblocks halting the innovation that could be coming out of the nanotechnology field. This 
truly emphasizes the point that perception can play a vital role in the technological progress, and 
people should be more open and understanding to the steps it takes to develop a new technology 
such as nanotechnology. 
4.4 Summary 
 Through the results that we received, we are now able to draw some conclusions about 
what we have found. In the next chapter, we will summarize our conclusion as well as provide 
38 
 
our sponsor, TEMAS AG, with recommendations about what they can do next to continue 
investigating the gap between nanotechnology and insurance, as well as to improve the 
knowledge of the insurance sector about emerging technologies, especially nanotechnology. 
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5.0 Conclusions and Recommendations 
In the following chapter, we present our conclusions after having analyzed the results we 
received. We also present recommendations to TEMAS AG and any other potential WPI IQP 
students that may continue forward with this project. 
5.1 Identify The Perceived Risks of Nanotechnology According to Companies and 
Researchers 
 Based on our interviews, we discovered that the misuse of nanotechnology and the public 
perception about nanotechnology are the main perceived risks of nanotechnology. Just as with 
many developed technologies, misuse can cause great harm to the user. Public perception is a 
risk as well because innovation of a potential technology can be halted if there is a negative 
association with nanotechnology. Many companies would not want to associate themselves with 
nanotechnology if there is such a negative opinion on the technology. Proper education about the 
handling and use of nanotechnology is important as well as properly informing the public so that 
they can see both the benefits along with the risks of nanotechnology. With proper education of 
nanotechnologies, the field can be improved as a whole. 
 There are several risk mitigation techniques that can be used to limit exposure to 
individuals who work with nanotechnology. One technique is to protect the lungs from any 
exposure to nanotechnology. This can be done by suspending any powders within a gel, working 
under a well-ventilated hood, and wearing protective masks. Many companies and researchers 
utilized these types of techniques to avoid nanotechnologies from aerosolizing since they worked 
with powders, while others used machines in the work space to avoid any physical contact when 
handling certain nanomaterials. This limited exposure would allow for workers to be at far less 
risk from nanomaterial based health implications. 
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5.2 Determine the Perception About the Role of Insurance Companies According to 
Companies and Researchers  
Through the eight interviews we conducted with advanced technology companies, we 
determined large companies believe that while insurance is important in protecting against 
problems that arise from risk, a proper risk management system actually mitigates some of the 
risk while insurance does not. We also determined small and medium sized companies believe 
that insurance is useful, and there are benefits in having insurance tailored towards advanced 
technology, such as nanotechnology. 
Based on our interviewees and communications with different insurance companies about 
the topic of insuring nanotechnology as well as the opinions we received from advanced 
technology companies and researchers, we can conclude that insurance companies do not view 
nanotechnology as an issue that requires full attention.  
5.3 Determine the Future Balance Between Risks and Benefits of Nanotechnologies 
With our results and analysis, we were able to conclude a lot regarding the perceived 
risks of nanotechnology. To start off with, we found that the perception of nanotechnology risks 
was much different among our research and among individuals in the field. With this 
discrepancy, it seems as if a lot needs to be done in the way of educating people working with or 
exposed to nanotechnology to ensure the right perceptions are found. Second, we found two 
different ways to approach nanotechnology from our interviews, one using the safe by design 
method (a more conservative technique) and one using a riskier approach of just treating it like 
any other technology. With the information pointing towards a lot of unforeseen risks, one might 
believe that a safe by design approach may be a better way to approach the progress of the 
nanotechnology field, however from talking with eight companies, the overwhelming idea was to 
take on a little bit of risk. Companies told us that like any other technology, there was going to 
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be risk and in order to innovate and make technological advancement one cannot eliminate risk 
entirely from a new field. With the planet looking more and more into nanotechnology as 
mentioned earlier in our paper, it seems as though the nanotechnology field is the logical next 
step for technological innovation and improving the quality of life our race. With what secrets 
still lie in the rather infant nanotechnology field, looking at it as a danger and not as a fountain of 
progress is the wrong approach. Based on our interviews, we concluded that as a race we must 
learn as we go and we will learn better ways to mitigate risk as we continue the development of 
nanotechnology.  
5.4 Recommendations  
 During the course of our project, there were certain issues pertaining to our project that 
we did not have time to investigate further. We present these issues in this section as a possibility 
for future research and for TEMAS AG to further investigate.  
 Although we decided to focus on the risks and benefits of carbon nanotubes, silica 
nanoparticles, and silver nanoparticles for the sake of time, these are only three types of 
nanotechnologies in a very broad field. Therefore, a thorough investigation through literature and 
using opinions from nanotechnology producers of different types of nanotechnologies should be 
done. Three potential nanotechnologies that can be considered are graphene, carbon black, and 
titanium dioxide. These nanotechnologies have a plethora of information about them from the 
literature and from producers.  
 Through one of our interviews with a researcher, we found out that there are insurance 
companies in the United States that deal specifically with nanotechnology. They did not mention 
the name of such an insurance company, but they explained that this insurance company focuses 
on giving a plan to a nanotechnology producer or user, and educating them on the risks as well as 
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risks assessment methods for nanotechnology. The process should help to lower the premiums 
that the nanotechnology company would have to pay for the insurance plan. Looking into these 
insurance companies and getting into contact with them would assist greatly in achieving the 
final goal TEMAS AG has set. This would give an example of one way to handle emerging risks 
from nanotechnologies, which could be brought up with insurance companies in Switzerland.  
5.5 Overall Contribution to TEMAS AG 
 Through our efforts, we were able to give TEMAS AG information regarding advanced 
technology companies and researchers’ perceptions about the risks and benefits of 
nanotechnology as well as their perceptions of insurance coverage surrounding nanotechnology.  
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Appendix A: Description of Sponsor 
The Technology Expertise Management Academy and Service (TEMAS AG), (2019) is a 
public, for-profit company that has been around for 20 years and is mandated by the Swiss 
Federal Office of Public Health (FOPH) to continue the development and implementation of the 
"Swiss Precautionary Matrix for Synthetic Nanomaterials.” The organization advises companies 
and institutions on the planning and implementation of innovations and supports projects with 
very close customer contact, paying close attention to schedules and budgets. The organization 
does not solely consult on technology or management individually; they combine both and view 
the technological impacts of change on the management and vice versa. 
When it comes to the structure of the company, the team is made up of seven diligent 
professionals (TEMAS AG, 2019). Andreas Halbleib is the CEO & owner, followed by our 
project’s two main contacts at TEMAS, who are Dr. Blanca Suarez-Merino, the Head of 
Technology and Expertise, and Dr. Christian Micheletti, the Project Manager. Their budget is 
covered by research projects. 
Currently, TEMAS AG is not partnered with any companies, but they do work with other 
companies on a timely basis (TEMAS AG, 2019). The previous partners of TEMAS AG were 
Lifo (Life Orientations) (2019) and Vision Zero (2019). Lifo is a useful tool used by more than 
20,000 organizations around the world. Life Orientations (2019) helps people based on their 
profile to boost motivation, engagement, teamwork and productivity in the workplace.  Vision 
Zero (2019) believes injuries at work are preventable using their three core values: safety, health 
and wellbeing. TEMAS AG are flexible when it comes to working with others. They are not just 
committed to government applications but also work with health and safety organizations at any 
scale. 
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Appendix B: Interview Protocol 
 We are a group of undergraduate students from the United States studying at 
Worcester Polytechnic Institute (WPI). We work with TEMAS to complete our Interactive 
Qualifying Project (IQP). The Interactive Qualifying Project (IQP) allows for students to connect 
science and technology with social issues by helping solve a particular real world problem.  
We are here to investigate the relationship between insurance companies and advanced 
technology companies with a focus on emerging risks. We would like to have a casual interview 
with you to discuss the risk management strategies your company takes as well as how your 
quality policy is involved in risk management. We are trying to provide insurance companies 
with much needed information regarding emerging risks as well as helping companies like yours 
to get the insurance you need and help mitigate some of the risk you need to worry about. All of 
the information you provide to us will be kept confidential, but we hope we can use some of the 
information we gain in a broader sense. We will be compiling all of the information we gather 
from our scheduled meetings with a variety of different technology companies. We appreciate 
your time and your cooperation. This will provide us with much needed information to complete 
our project. Our contact information is gr-nanotechnologies@wpi.edu.  
 
Thank you in advance for taking the time to answer these questions,  
Michael Connor, Tristan Lepage, Lindsay MacInnis, Eric Macorri 
 
Questionnaire 
 
1. What are the major research projects your lab/company is working on and the associated 
risks? 
a. What does emerging risks mean for your company? 
b. What are the main critical issues involved in your research projects? 
2. When looking at nanosafety from a company perspective, what special considerations 
should be taken into account? 
3. What are some ways your company is approaching safety for nanotechnology?  
4. How are the regulations affecting the industry and how are they protecting the general 
public in the long run? 
 
5. Are the current published ISO standards adequate for the development in the 
nanotechnology field? 
 
6. Has anyone been severely injured from general exposure to nanomaterials? 
 
7. In what ways should people deal with the disposal of nanomaterials? 
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8. How have the long term effects of nanotechnology been analyzed? 
 
9. Do you have a normal general liability coverage or a special coverage for nanomaterials? 
 
10. Are there certain associated risks that you would like to have better coverage for? 
 
11. How does your quality policy and risk management system reflect the associated risks 
with your company’s products? 
a. Can you briefly describe your risk management system? 
 
12. Would you be willing to share data with your insurance company or pay extra for better 
risk prevention services? 
13. What do you see as the main risks of nanotechnology? 
14. In general, how do you think insurance companies should handle emerging risks in 
today’s world? 
15. In your opinion, when is an emerging technology no longer emerging? (Standards, Size 
of market sector) 
 
16. Would we be able to use some of your responses in our IQP paper for school? We will 
send you the section of the paper that we use this information for your approval. We will 
also not use your name if you do not want us to do so. 
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Appendix C: FDA’s Approach to Regulation of Nanotechnology 
Products 
https://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm602536.htm 
https://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm402230.htm 
 
As a public health agency using scientific information to make regulatory decisions about products 
ranging from cosmetics to chemotherapy agents to food packaging, FDA has long encountered the 
combination of promise, risk, and uncertainty that accompanies emerging technologies. 
Nanotechnology is not unique in this regard. Materials can exhibit new or altered physicochemical 
properties at nanoscale dimensions, which can enable the development of novel products. The very 
changes in biological, chemical and other properties that can make nanotechnology applications so 
exciting, however, also may merit examination to determine any effects on product safety, 
effectiveness, or other attributes. 
The application of nanotechnology may result in product attributes that differ from those of 
conventionally-manufactured products, and thus evaluations of safety or effectiveness of FDA-
regulated products that include nanomaterials or otherwise involve the application of nanotechnology 
should consider the unique properties and behaviors that nanomaterials may exhibit. However, FDA 
does not categorically judge all products containing nanomaterials or otherwise involving the 
application of nanotechnology as intrinsically benign or harmful. FDA will regulate nanotechnology 
products under existing statutory authorities, in accordance with the specific legal standards 
applicable to each type of product under its jurisdiction.  
Consistent with Executive Order 13563 on improving regulation, as well as with the White House 
policy statements on regulating emerging technologies and applications of nanotechnology, FDA 
supports innovation and the safe use of nanotechnology in FDA-regulated products under 
appropriate and balanced regulatory oversight. By enhancing its scientific expertise and tools 
necessary to assess the safety and, as applicable, effectiveness of products (see FDA’s 
nanotechnology regulatory science research plan), FDA can enable the responsible development of 
products with new and beneficial properties. FDA intends to ensure transparent and predictable 
regulatory pathways grounded in the best available science.  To that end, FDA’s regulatory 
approach will have the following attributes: 
 FDA is maintaining its product-focused, science-based regulatory policy. Technical 
assessments will be product-specific, taking into account the effects of nanomaterials in 
the particular biological and mechanical context of each product and its intended use. And 
the particular policies for each product area, both substantive and procedural, will vary 
according to the statutory authorities. We advise manufacturers to consult with the FDA 
early in their development process to facilitate a mutual understanding of the scientific and 
regulatory issues for their nanotechnology products. 
 FDA’s approach respects variations in legal standards for different product-classes. 
Food additives are considered safe when there is a reasonable certainty of no harm from 
their intended use[1].  Drugs, by contrast, are evaluated not only on the basis of their risk 
profile but also their predicted benefit.[2] These differing legal standards demonstrate how 
different contexts could lead to different regulatory outcomes, even if two products present 
the same level of risk. Other products regulated by FDA are subject to yet different 
standards for safety or effectiveness. The result may be divergent regulatory outcomes for 
different product classes and different applications of nanomaterials, even where objective 
measures of risk are similar. 
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 Where premarket review authority exists, attention to nanomaterials is being 
incorporated into standing procedures. For example, new drugs, new animal drugs, 
biologics, food additives,[3] color additives, certain human devices, and certain new 
dietary ingredients in dietary supplements are subject to premarket review requirements. 
Premarket review processes for these products require applicants to submit data to 
answer questions related to the safety, effectiveness (where applicable), or regulatory 
status of the product. Individual premarket review procedures include attention to whether 
the use of nanomaterials suggests the need for additional data on safety or effectiveness, 
as applicable[4]. 
 Where statutory authority does not provide for premarket review, consultation is 
encouraged to reduce the risk of unintended harm to human or animal health. Some 
FDA regulated products, such as dietary supplements (except certain new dietary 
ingredients), cosmetics (except color additives), and food (except food or color additives) 
are not subject to mandatory premarket review. In these cases, FDA relies on publicly 
available or voluntarily submitted information, adverse event reporting (where applicable), 
and on post-market surveillance activities, to provide oversight.  Where nanotechnology 
applications are involved, FDA encourages manufacturers to consult with the agency 
before taking their products to market. Such consultation can help FDA to advise 
companies, review safety information, and design any necessary post-marketing safety 
oversight. 
 FDA will continue post-market monitoring. FDA will continue to monitor the marketplace 
for products containing nanomaterials and will take actions, as needed, to protect 
consumers. 
 Industry remains responsible for ensuring that its products meet all applicable legal 
requirements, including safety standards.  Regardless of whether products are subject 
to premarket review or authorization, manufacturers are required to ensure that their 
product satisfies applicable safety standards and complies with other applicable 
requirements. Therefore, industry must work with current information in product 
development, and continue to monitor products once marketed. FDA encourages industry 
to consult early with the agency to address questions related to the regulatory status, or to 
the safety, effectiveness, or other attributes of products that contain nanomaterials or 
otherwise involve application of nanotechnology.  These early consultations afford an 
opportunity to clarify the methodologies and data that will be needed to meet the 
sponsor’s obligations. Additional public meetings or workshops may be held to advance 
regulatory science, identify product-specific data needs, or seek input on specific issues. 
 FDA will collaborate, as appropriate, with domestic and international counterparts on 
regulatory policy issues. FDA engages in policy dialogue with other U.S. government 
agencies through the Emerging Technologies Interagency Policy Coordination Committee 
and other forums, among other things, to contribute to overarching U.S. government 
policies relevant to nanotechnology and, as appropriate, coordinate its policy activities. 
FDA also works with foreign regulatory counterparts to share perspectives and 
information on the regulation of nanotechnology products and their intended uses. 
 Both for products that are not subject to premarket review and those that are, FDA will 
offer technical advice and guidance, as needed, to help industry meet its regulatory 
and statutory obligations. FDA prepares guidance documents for its staff, 
applicants/sponsors, and the public to describe the agency’s interpretation of or policy on 
a regulatory issue. Guidance documents will emerge over time, and (depending upon the 
product-class) will address interpretation of relevant statutory and regulatory standards, 
and provide guidance on the technical data needed to meet those standards (see list 
below for guidances already published). FDA will tailor guidances to the unique 
confluence of the statute governing the product-class, the level of scientific knowledge 
relevant to those applications, and the likely extent of effects on human and animal health. 
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For additional information or specific questions related to FDA’s nanotechnology regulatory 
policies, contact: 
Office of Policy 
Office of the Commissioner 
U.S. Food and Drug Administration 
10903 New Hampshire Avenue 
Silver Spring, MD 20993 
Phone: 301-796-4830 
Fax: 301-847-3541 
 
[1] See Federal Food Drug and Cosmetic Act (FFDCA) sections 409 (21 U.S.C. 348) and 21 CFR 
170.3(i). 
[2] See FD&C Act § 505 (21 U.S.C. 355); and 21 CFR 330.10(a)(4)(iii). 
[3]  Includes food contact substances, such as food packaging. 
[4]  Premarket review may also address issues other than safety or effectiveness,  e.g. product identity 
verification and manufacturing controls.  
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Appendix D 
Disclaimer: The answers to these questions are kept anonymous for the safety of our 
interviewees. Some questions did not apply to certain interviewees, so they were omitted. 
Additional questions were added in some cases to make the interview more conversational. 
 
Interview 1 
1. What are the products your company produces and the associated risks? 
 This company is involved with many different products, including manufacturing 
graphene, nanomaterials and nanoclays. They are trained to use these products and to 
avoid contamination. They may be taking more risks than they intend to and they care 
more about the risk of the chemicals than the nanomaterials.  
2. Does your company have insurance for these types of products? What level of 
coverage does your company have? 
 The company has special insurance for working with chemicals, but do not have 
anything that relates to nanomaterials. They believe that there are not many companies 
with insurance for nanomaterials. There is no special regulation for insurance with 
nanotechnology.  
3. Within the associated risks, are there any that insurance companies are not willing 
to insure? 
 They believe that insurance companies do not see nanotechnology as that great of 
a risk compared to chemicals. Insurance companies don’t understand nanotechnology 
which makes it difficult to regulate. Maybe they will offer insurance in the future.  
4. How does your quality policy and risk management system reflect the associated 
risks with your company’s products? 
 They are using the same policy for working with chemicals. They are following 
regulations on the national level and not doing anything special for the risk of 
nanotechnologies.  
5. Would you be willing to share data with your insurance company or pay extra for 
better risk prevention services? 
 If it was her choice no, she would be sure that if there was better insurance 
offered that they would pay the price.  
6. How do you think insurance companies should handle emerging risks in today’s 
world? 
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 It is important for the insurance companies to know about the advancing 
technologies when they want to offer them insurance. They should have more knowledge 
about the risks and understand what they are insuring.  
7. When is an emerging technology no longer emerging? 
 When the risks are well evaluated and everyone understands the product. When 
the product is out in the market and very well known.  
 
Interview 2 
1. What is your specific role within the company? 
 The role of this interviewee is the responsibility for the equipment research and 
development team within endodontics. The name of this position is innovation and 
technology.  
2. What are the products your company produces and the associated risks? 
 This company produces medical devices related to dentistry as well as software 
for some of the medical devices. The interviewee explained that any associated risks 
would be to the patient in which their devices are used on. This would be due to the 
misuse of the product and not a flaw in the product itself. They also mentioned that 
cybersecurity is a large risk in their view.  
3. Does your company have insurance for these types of products? If not, why? 
 The interviewee was not sure if they had insurance for their products. They 
explained that they do require insurance for any clinical trial due to the experimentation. 
They continued to talk about how they don’t find their products risky due to the 
regulations that they follow. There is more risk in a hospital environment than in their 
own products.  
4. In general, how do you think insurance companies should handle emerging risks in 
today’s world? 
 They believe that insurance companies should be there in order to reduce or assist 
a company once the risk has appeared. They also believe that a good risk management 
system is more important than insurance when dealing with emerging risks.  
5. In your opinion, when is an emerging technology no longer emerging? (Standards, 
Size of market sector) 
 Once the product is well understood and out on the market then it is no longer 
emerging. It would be a technology that they would invest in.  
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Interview 3 
1. Do you have a specific role within the company? 
 She is responsible for material production. 
2. What are the products the company produces and the associated risks?  
They make electrodes for EEG or ECG measurements.  
a. What are your products made of?  
These are made of a new, soft conductive material, it starts with a silicon 
rubber and then filled with conductive particles. They use carbon black particles 
in the nano range and silver particles 2-4 micrometers. 
b. What processes do you use to create your products? 
They have established a safety protocol to handle the unsafe particles. 
Once the customer uses the product, they don’t want the particles to come out of 
the matrix. 
3. Does your company have insurance for these types of products? What level of 
coverage does your company have? 
 They have standard personal insurance. The Standard Operation Protocols (SOP) 
specifies every step in handling the carbon black nanoparticles. All hands-on work is 
produced under a hood. 
4. Would you be willing to share data with your insurance company or pay extra for 
better risk prevention services? 
 If she was the boss of the company, she would pay more or share data in order to 
be better protected. 
5. How do you think insurance companies should handle emerging risks in today’s 
world? 
 There should be some type of specialized insurance for advanced technology, 
such as nanotechnology. There should be laws in place to protect workers from the risks 
of emerging technology. There should be fines from insurance companies or the 
government if procedures are not done correctly. 
6. When is an emerging technology no longer emerging? 
 It is no longer emerging when a large amount of the population is using it every 
day. When the size of the market or risks are understood.  
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Interview 4 
1. What is your specific role at this research laboratory? 
 They are in charge of the laboratory that they work at. They take care of all 
researchers that work within the facility as well as take care of the risk management 
system set in place. 
 
2. What are the products your laboratory researches and the associated risks? 
 They research tissue engineering and the associated risks would be the use of 
chemical within the laboratory. There would be no risks for the end-user. 
 
3. Does your laboratory have insurance coverage? 
 Everything is covered by the institution that they work under. There is general 
liability insurance for everyone that works in the research laboratory.  
 
4. Are there certain associated risks that you would like to have better coverage for? 
 They do not have any high-risk projects, but they do have chemicals that come in. 
They rely on the safety of the products that they receive from the supplier. Everyone in 
the laboratory must be well educated and trained when using these chemicals. 
  
5. How does your quality policy and risk management system reflect the associated 
risks with your company’s products? 
 Having a perfect safety regulation is hard to implement and could potentially 
reduce productivity. They must rely on common sense of the people that work in the 
laboratory. They also said that insurance is not the way to go but risk prevention is. They 
give an example of how somebody may get cancer from improperly working with 
chemicals but insurance won’t fix the issue. Prevention is simpler and less expensive than 
insurance.  
 
6. In general, how do you think insurance companies should handle emerging risks in 
today’s world? 
 Emerging risk is difficult to handle.  
 
7. In your opinion, when is an emerging technology no longer emerging? (Standards, 
Size of market sector) 
 Emerging is something that is not yet well-known and you do not know the risk 
associated with it. If we can estimate about 90-95% of the consequences, then it’s not an 
emerging technology. 
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Interview 5  
1. What is your specific role within the company? 
 Business Development 
2. What are the products your company produces and the associated risks? What are 
the main critical issues involved in your products? 
 There are not any risks in general. Cybersecurity can be an issue to some extent, 
but it is the responsibility of their company to deal with cybersecurity. They develop 
software for a specific customer and then they leave up any issues afterwards to the 
customer. 
 
3. Does your company have insurance for these types of products? 
 They have standard risk insurance. They are not covered for their data storage, but 
they do not store any live data.  
4. Are there certain associated risks that you would like to have better coverage for? 
 Yes, she thinks it is important to have more coverage. 
5. How does your quality policy and risk management system reflect the associated 
risks with your company’s products? 
 Everything they do is documented.  
6. Would you be willing to share data with your insurance company or pay extra for 
better risk prevention services? 
 She expressed they would pay extra for better coverage, however she would not 
share data with the insurance company without a clear big outcome. 
7. In general, how do you think insurance companies should handle emerging risks in 
today’s world? 
 She thinks they should handle these emerging risks similar to health insurance, 
some parts are covered by risk insurance. The insurance companies should focus on 
preventing the risk.  
8. In your opinion, when is an emerging technology no longer emerging? 
 Once an emerging technology has established a good understanding and is 
available it is no longer emerging. 
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Interview 6 
1. Since the main purpose of ContactPointNano is to provide information about the 
safe handling of nanomaterials, has it helped involve insurance companies or create 
better risk management systems? 
 Contactpointnano was put in place after having some Swiss Plan with synthetic 
materials. The aim is to react with the emerging technology, nanotechnology, and put it 
into a bigger context. One of the first elements was to see if they needed special attention 
for nanotechnology. The goal is to focus on the benefit of the society, bringing 
knowledge to publication, making sure its the right project for the right phase of 
development, and focusing on safe handling and regulation. There is a huge mess in 
Switzerland trying to combine the science, the industry, and the insurance. 
Contactpointnano is a team that is taking a request from clients, such as start-ups and 
small and medium sized companies, that have questions about safe handling and 
regulation. Contactpointnano is a neutral platform between companies and the federal 
government. 
 At the very beginning of contactpointnano, SwissRe was active. However, now 
they have showed minor interest. If the material has high uncertainty, then they will cost 
more. 
2. What are the major research projects your lab is working on and the associated 
risks? 
 Their projects push to understand the process of nanosafety. There are plenty of 
different types of materials that they have looked at. Their research is application driven, 
they have looked into potential risks for nanoparticles in paint, packaging, medical 
applications, and food additives. They know a lot about nanoparticles and are now 
starting to look into nano medicine.  
a. What does emerging risk mean for your lab? 
 All of his research is emerging risks. All that is new makes him curious, 
he looks at the safety and the risk. 
3. What are your thoughts about the recent titanium dioxide ban in France? 
 This ban was overreacting. They need to consider a broader view and do more 
research. The titanium dioxide in sunscreen is coated, not pure, they downsize the 
material in order to make it transparent. Innovation slows down when the question of 
whether it is dangerous is asked. Integrate risk potential within early development using 
the safe by design approach. The safety and innovation wheels need to work together and 
need to find a balance between the two. 
4. What are some ways your research is approaching safety for nanotechnology? 
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 Using the safe by design approach, the entire process is understood before starting 
instead of step by step. They integrate potential side-effects early within the process. 
5. How are the regulations affecting the industry and how are they protecting the 
general public in the long run? 
 Some of the nanotechnology is overregulated. Due to the number of different 
ways to measure the particles, there is no clear size. The measurements go back and forth 
with the regulations because they can get plenty of different sizes and the regulatory 
doesn’t say which way to measure. People will normally take the measurement that says 
the technology is not nano in order to avoid those regulations. These regulations can slow 
down the innovation. 
6. Are the current published ISO standards adequate for the development in the 
nanotechnology field? 
 The ISO standard needs nearly 10 years to update. They are in the process of 
pushing for new ISO standards. They have no notified bodies that are certified to deal 
with nano, and this is identified as a gap in Switzerland. 
7. Has anyone been severely injured from general exposure to nanomaterials? 
 Combustion derived particles have an increased rate of mortality, not the 
engineered materials. There have been no cases for perfectly engineered materials. 
Inhalation tends to cause issues, for example silicosis and asbestosis. There could be 
some synthetic fibers that could have nano-dimension. The only problem he could 
imagine is with the fibers not the particles. When they deal with fibers, they take 
precautionary methods to protect the people working in the lab. They also try to avoid 
powders or suspend them within a substance. 
8. In what ways should people deal with the disposal of nanomaterials? 
Treat the disposal of nanotechnology as if it was an extreme risk, this may cost 
more but is on the safe side. People should use the precautionary principle. Don’t know 
the impact on the environment. Treat nanotechnology as the highest level of chemical.  
9. How have the long term effects of nanotechnology been analyzed? 
Long term effects are an extremely complicated system to tackle. We are often 
exposed to things that we don’t know the long term effect of, and we don;t know how 
things will react with each other. Mice and rats don’t live long enough to use to study the 
long term effects. People can’t control all of the co-exposures. There needs to be 
monitoring from the first exposure to the disease. The longer the incubation period, the 
more difficult it is to figure out what caused it because there needs to be a certain amount 
of evidence. Long term effects are not just isolated to nanotechnology.   
10. Do you have a normal general liability coverage or a special coverage for 
nanomaterials? 
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 Part of a federal institution, he doesn’t deal with the insurance so he is not sure 
exactly what they have. 
11.  How does your quality policy and risk management system reflect the associated 
risks with your research projects? Can you briefly describe your risk management 
system? 
 They consider everything as potentially critical. They realize the lung is the most 
susceptible, so they avoid powders at all costs. It is all about knowing what the risks are. 
12. Would you be willing to share data with your insurance company or pay extra for 
better risk prevention services? 
 He does not handle the insurance so he can’t answer from his perspective. 
However, he can imagine companies are not in favor of sharing secrets and will probably 
have to pay more. 
13. What do you see as the main risks of nanotechnology? 
 Misuse of nanotechnology would be the greatest risk. The general misuse of novel 
technology is always a risk. Free particles would also be another risk. Nanotechnology 
used in different fields or dual use would fall under misuse. 
14. In general, how do you think insurance companies should handle emerging risks in 
today’s world? 
 The insurance companies should be supportive and not always see the worst case. 
The risks and benefits should be well calculated. They need to find the balance between 
what needs to be regulated and what needs to be explored. If everything is banned, we 
lose the potential to help people. For example, cars are dangerous and were once viewed 
as very dangerous, but we have adapted. It is all about the correct and safe use, and the 
same has to be done with emerging risks. The emerging technology currently has to 
prove zero risk  and then adapted, understandable emotionally but not fair. 
15. In your opinion, when is an emerging technology no longer emerging? 
 As long as we are in the hype, then it is still emerging. Once the technology has 
been consolidated and we know how to use it well, then it is no longer emerging. 
Different societies are in different sections of this cycle, it could be more regional or 
generational. Could depend on different populations and how much people have been 
surrounded by them. These technologies are no longer emerging as you get used to it. 
 
 
 
63 
 
Interview 7 
1. With your products being sensors for detecting nanoparticles, can you briefly 
discuss how these specific sensors work?  
 The technology is material selective. They started out with carbon nanotubes and 
graphene. Then move on to sensors for silica, metal oxides, carbon black. There may be a 
new regulation for carbon black in a few countries in the future.  
2. Does your company do specific research on the risks of nanotechnology and 
dangerous exposure levels? 
 The company watched the research of the risk. The have a health and safety 
person with a background in nanomaterial science and bio-eng who monitors the 
regulations. Often the regulation has nothing to do with science and is mostly driven by 
political issues. The regulations depend on the material and the country, and how the 
risks are perceived from the government.  
3. When looking at nanosafety from a company perspective, what special 
considerations should be taken into account? 
 It is their daily business to take nanosafety into account. “We’re too careful” 
because they know the risks and the potential outcomes. They get samples from large 
companies with dangerous materials in a zip-loc bag or samples that are well packaged 
and taken care of. This can also be an industry topic, certain industries are not aware of 
the risks. For example, the battery industry, lithium-ion people don’t take the necessary 
precautions when dealing with hazards. They often don’t wear gloves and don’t think 
there is anything wrong with a little bit of dust because they are unaware of the 
nanosafety. There are some companies, often large companies that are too afraid of the 
risks and then this causes a delay in innovation.  
4. What are some ways your company is approaching safety for nanotechnology? 
 They handle everything in a flow box. There is no powder handling outside of the 
biological flow box. They handle very small quantities of nano. Some nanomaterials can 
be aerosolized very easily while others don’t. They take safety one step further than 
necessary as a precaution. 
5. How are the regulations affecting the industry and how are they protecting the 
general public in the long run? 
 Materials can change depending on how they are manufactured. Companies that 
handle larger quantities have less exposure risk. 
6. Are the current published ISO standards adequate for the development in the 
nanotechnology field? 
 They read the ISO standards, however they do not follow them because they don’t 
exactly apply. There is more work on the toxicity side, so they should have set standards 
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before pouring tons of money into toxicity research. For many companies the standards 
are helpful. It is good for companies that can take the standards to start with and then 
change things based on what works best for their company.  
7. Has anyone been severely injured from general exposure to nanomaterials? 
 He does not know of anyone that has been endangered by new nanomaterials. 
Most people get harmed from old materials rather than new materials.  
He does not think safe by design is the way to go. He thinks it’s impossible to 
design safely because you can’t know all the potential risks. From a health and safety 
point it may be okay, however for research and innovation it may not be good. When 
you’re innovating, you can assume a little bit of the risk so that you can improve more. 
He thinks that the safe by design approach causes them to miss out on potential, you 
should take on some risk in order to move on in the field. 
8. How have the long term effects of nanotechnology been analyzed? 
 Long term effects are just monitored. The consumer exposure is very little, it is 
mainly the producers that are affected. Most of the materials are not an issue. 
9. What are your thoughts on the recent titanium dioxide ban in France? 
The titanium dioxide banning is a perfect example of the political drive. It is 
overreacting. France isn’t very streamlined because the regions act differently. 
10. In what ways should people deal with the disposal of nanomaterials? 
This can change from country to country. In Switzerland they incinerate 
everything in concrete plants. They don’t have leakage into the water stream, but most 
countries don’t do that. It is a case by case topic. Disposal of certain materials is difficult 
and the industry isn’t as active on this.  
11. Do you have some sort of insurance coverage for nanomaterials? 
 They do have insurance coverage for nanomaterials. Since there is little 
knowledge and interest coming from insurance companies, the premiums are kept high 
and they charge for higher risk. Their insurance plan specifically talks about 
nanotechnology. Many companies can’t get coverage or coverage is too expensive. Some 
companies won’t include the fact that they deal with nanotechnology and mislabel 
themselves, so that they can avoid the more expensive insurance. 
 There are some brokerage companies in the US that go to companies, get them 
coverage, help them mitigate risk and lower their premiums. This is a much more touchy 
subject in the US, a lot of companies here don’t get inspected. People in Switzerland are 
less likely to threaten litigation, so companies are much more relaxed and don’t have as 
many regulations. 
12. How does your quality policy and risk management system reflect the associated 
risks with your company’s products? 
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Be aware of what’s going on, use best practice, and always stay on top of what’s 
going on in the industry. 
13. Can you briefly describe an adequate risk management system for nanotechnology 
and where would your products fall in line with this? 
 Make sure everyone is aware of what you’re doing and keep searching for gaps. 
Be thorough with the risk management system and be well educated to deal with the 
materials that you’re handling. 
 There’s a shift between a risk management system on paper and getting real data 
every day from the sensors they make. There is a much faster time frame to help react, 
prevent sooner rather than later. 
 Many companies don’t want to know what’s going on or they don’t care. They 
just want to sell their products and risk is a cost not a profit. Risk management is much 
more laid back in Switzerland than the US because of the lack of litigation.  The US is a 
very important market for this company. Depends from country to country, but the lack 
of litigation is the problem. 
14. Should people be willing to share data with their insurance company or pay extra 
for better risk prevention services? 
 Sharing data or paying more would be a case by case procedure. If sharing data 
would reduce premiums, then some companies may be willing to do that. Could see it 
happening, but a lot of companies do not want to share data with anyone because this is a 
very touchy issue.  
15. What do you see as the main risks of nanotechnology? 
 The main risk has nothing to do with the materials or toxicity itself, but with 
public perception. The public perception can sink or display an industry. For example, 
some journalists published saying that carbon nanotubes could be the new asbestos, and 
this opened up a conversation the public could not handle. The public perception can be 
shaped by outside forces from the industry. 
16. In general, how do you think insurance companies should handle emerging risks in 
today’s world? 
 Insurance companies need to get out of the old style thinking of looking 
backwards and looking at past risks. They have to change their mindset to look at real 
data and adapting to a business style. This switch in thinking is very difficult. This 
thinking is totally different and they haven’t realized it. They’re just making money and it 
is difficult to switch their thinking to offer more attractive and tailored premiums, 
changing depending on how the company is doing.  
 This company regularly talk to their insurance company and if they are making 
money, they don’t care to change. 
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17. In your opinion, when is an emerging technology no longer emerging? 
 This technology is no longer emerging when a regular customer can approach a 
manufacturer and ask to buy it and apply it to their work.  
 
 
Interview 8 
1. What is your specific role at this company? 
 He is the founder and director of the company and leads everything that goes from 
source identification and risk assessment and recommendation. Has a large background in 
nanotechnology. 
2. What are the major occupational and environmental risks nanotechnology poses? 
 The largest health risk with carbon nanotubes is the inhalation risk. This is 
considered to have similar toxicity to asbestos.  
3. What do you think regarding the environmental risk of silver nanoparticles? 
 This brings the question of the quantity of these particles that get into the 
environment. He can imagine disturbances in bacteria as well as a change in our 
antibiotics. This might cause more resistance in bacteria and could change biofilms in a 
way that we don’t want. 
4. When looking at nanosafety from an occupational perspective, what special 
considerations should be taken into account? 
 They should acknowledge that nanomaterials and nanotechnology have different 
types of risk that need to be addressed specifically. Treat nanomaterial as a new material 
and be careful when looking at it. Look at it’s form and not just lump it in as a chemical. 
5. What are some ways your company is approaching safety for nanotechnology? 
 He advises the government and companies on how to approach the risk of 
nanomaterials and how to address the development phase. He advises companies that are 
in the beginning phase that have not even begun developing their technologies. It’s 
completely doable to handle toxic materials it just depends on how you handle the risk. 
For example, pharmaceutical companies handle toxic raw materials all the time, but there 
are professionals that handle the risk. They make sure there’s not too much raw material 
and that it doesn’t go out into the environment or endanger anyone.    
6. How are the regulations affecting the industry and how are they protecting the 
general public in the long run? 
 In the nanotechnology field, the public fear and the public hype is affecting the 
industry much more that the regulations. Many companies decide not to go into 
nanotechnology development because they can’t assess the risk of public perception. For 
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example, there is a company in Basel that created a material better than its predecessor, 
but because it is nano and some companies don’t want to be associated with a bad nano 
company, they are too afraid to take the risk. It’s a small company and if they lose even a 
quarter of their sales of their main product then they would be in trouble. Public 
perceptions are driving nanotechnology more than regulations. 
7. Has anyone been severely injured from general exposure to manufactured 
nanomaterials? 
 Nanomagic are nanoparticles involved in China. They were exposed to a lot of 
nanoparticles and he would not be surprised if there were issues that would come over 
time. There are few studies that if workers are exposed to too high of a concentration of 
nanoparticles they would likely be affected in the long term. 
8. In what ways should people deal with the disposal of nanomaterials? 
Disposal of nanomaterials should be done correctly and it should be treated the 
same way as chemicals, it can’t be dumped anywhere. By looking at the specific 
nanomaterial and determining the level of toxicity you can decide the approach you will 
take. Many nanomaterials can be digested by acids but highly toxic nanomaterials have to 
be disposed into chemical waste and are incinerated. The swiss government has a 
nanowaste disposal ordinance but believe people should be better informed on how to 
properly do it. However, he doesn’t see disposal as a major issue of nanotechnology.  
9. How have the long term effects of nanotechnology been analyzed on both the human 
body and the environment? 
 There have been a lot of theoretical studies. They study the possible effects on the 
environment. The missing part is the occupational health set-ups to study the long term 
health effects of workers. There are some people that are not in favor of epidemiological 
studies. Insurance companies don’t like the uncertainty of risk. They have some 
information about exposure file and acute toxicity, but they lack epidemiological 
knowledge. 
10. Are there specific hazards regarding nanotechnology that companies should have 
insurance coverage for? 
Every company has to assess their risk and decide on a portfolio on which risks 
are likely catastrophic if they occur. They should make sure to have these risks insured or 
taken care of. He believes risk assessment comes first and then insurance. 
11. How should a company’s quality policy and risk management system reflect the 
associated risks with products containing nanotechnology? 
 They should ensure its nano label and familiarize with the markets risk 
management and government strategies to see if it applies to them. Look at the highest 
risks to see what strategies they recommend and then see how they can combine them in 
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their company. Every company has to assess their risk and decide on a portfolio on which 
risks are likely catastrophic if they occur. They should make sure to have these risks 
insured or taken care of, risk assessment first, then insurance. 
12. Should companies be willing to share data with their insurance companies or pay 
extra for better risk prevention services regarding nanotechnology? 
 If the company cannot share data, insurance would not give them insurance. If the 
company was hiding stuff or not showing everything up front, the insurance would not 
want to insure. Basically a company needs to share important information regarding 
nanotechnology. 
13. What do you see as the main risk of nanotechnology field as a whole? 
 One main risk is the point of the material hazard; the second risk is the risk being 
overestimated by the general public that leads us to be stuck with nanomaterial solutions 
that are not good for human health or the environment. Even though innovation is totally 
safe and the material could pose great benefits. The over dramatization of the risk of nano 
has halted some companies because they fear of being labeled as a bad nano company. 
Some companies are downplaying the risk and assume it’s similar to chemicals and this 
backfires. This is causing a halt of innovation with some companies because they didn’t 
go with some products that are not dangerous only because of the fear of being labeled as 
a bad company. 
14. In general, how do you think insurance companies should handle emerging risks 
like nanotechnology in today’s world? 
 Insurance companies should be open to see both the positive and negative sides 
when discussing with scientists. He mentioned that discussions should not just be with 
toxicologist but rather include environment and health scientists and risk analysts. Many 
toxicologists don't understand the difference between hazards and risks. He also 
mentioned that insurance companies should think about possible scenarios but that should 
be reasonable. 
15. In your opinion, when is an emerging technology no longer emerging? 
Once it becomes mainstream and becomes a known substance. Look at the 
production rates and how widely it is used, but it can become misleading if you determine 
it by the production rate. Once it becomes a widespread technology that everyone knows 
how to use it.  
 
